U.s. food and drug administration, Federal agency

Washington [US], July 3 : Protein aggregates build up with age and have been linked to neurological illnesses such as Alzheimer's, Parkinson's, and Huntington's disease. A recent work from the Gothenburg University Nystrom lab, in conjunction with the Max Planck Institute for Biology of Ageing in Germany, offers a novel, designed technique that allows protein aggregation to be spatially manipulated in both budding yeast and human cells.Many neurodegenerative diseases like Alzheimer's, Parkinson's or Huntington's disease are associated with the aggregation of misfolded proteins but whether or not these aggregates contribute to these diseases is not clear.The research group of Professor Thomas Nystrom from Gothenburg University was able to export such protein aggregates from cells in an engineered manner, which was published in the journal Nature Communications. The system was first developed in the widely-used model organism, budding yeast, but was extended also for use in human cells.Free of protein aggregatesThe authors achieved this synthetic cellular export system by fusing an aggregate-binding protein to a daughter-cell-targeting factor such that when the daughter cell is pinched off, the mother cell is free of protein aggregates. This approach was effective in dealing with endogenous, age-associated protein aggregates, as well as with mutant Huntingtin aggregates associated with the Huntington's disease.Using this daughter targeting system, they showed that the export of mutant Huntingtin protected yeast mother cells from cell death suggesting that large Huntingtin aggregates may be highly toxic and contribute to the disease, a trait that has been widely debated.Potential future therapy"To our knowledge this is the first demonstration that protein aggregates can be exported from cells in a controlled, engineered manner. Other kinds of cellular damage might be also exported from cells with adapted versions of our targeting system", says Dr. Arthur Fischbach, postdoc and the lead author of the study."Although we currently lack supporting data, there is a possibility that the ATS concept could be employed in the future as a potential novel therapeutic approach for neurodegenerative diseases or at least for gaining a better understanding of them. Given the urgency, there is a strong demand for innovative therapies in this area", he concludes.Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

U.s. Food And Drug AdministrationFOLLOW

U.s. food and drug administration, Latest News

Washington, July 4 The US Ambassador to Russia, Lynne Tracy met jailed Wall Street Journal reporter Evan Gershkovich ... ...

Washington, July 3 Two men dressed in dark clothes walked up to the gate of the Indian consulate ... ...

Washington, July 3 The US said it “strongly condemns” reported vandalism at the Indian consulate in San Francisco. ... ...

Los Angeles [US], July 4 : Twitter users will soon need to be verified to use TweetDeck. The change ... ...

Los Angeles [US], July 3 : Legendary actor Robert De Niro's grandson Leandro De Niro has passed away. He ... ...

Los Angeles [US], July 3 : Star couple Kit Harington and Rose Leslie have been blessed with their second ... ...

New Delhi, July 3 The BSE Sensex scaled 65,000 on Monday led by Reliance Industries. Indian markets have been scaling ... ...

Washington [US], July 3 : Protein aggregates build up with age and have been linked to neurological illnesses such ... ...